Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Market Analysis & Valuation

UpdatedJan 26, 2026
DataAggregated Company Financials
Companies133
  • 7D2.5%
  • 3M12.9%
  • 1Y-15.8%
  • YTD8.7%

The market has been flat in the last week, however the Consumer Discretionary sector is down 6.0%. Unfortunately though, the market is down 16% over the past year. Looking forward, earnings are forecast to grow by 5.9% annually.

Trending IndustriesBiotech

Market Valuation and Performance

Has the Danish Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 26 Jan 2026DKK 4.5tDKK 1.9tDKK 260.8b17x17.4x2.3x
Wed, 24 Dec 2025DKK 4.2tDKK 1.9tDKK 260.5b16.2x16x2.1x
Fri, 21 Nov 2025DKK 4.0tDKK 2.0tDKK 262.7b14.6x15.1x2x
Sun, 19 Oct 2025DKK 4.1tDKK 1.9tDKK 287.5b15x14.1x2.1x
Tue, 16 Sep 2025DKK 4.0tDKK 1.9tDKK 287.1b15.3x14x2.1x
Thu, 14 Aug 2025DKK 3.9tDKK 1.9tDKK 272.1b15x14.2x2x
Sat, 12 Jul 2025DKK 4.5tDKK 1.9tDKK 261.9b15.8x17.2x2.4x
Mon, 09 Jun 2025DKK 4.7tDKK 1.9tDKK 263.4b15.7x17.9x2.5x
Wed, 07 May 2025DKK 4.4tDKK 1.9tDKK 259.1b14.6x16.9x2.3x
Fri, 04 Apr 2025DKK 4.4tDKK 1.9tDKK 259.8b14.1x16.8x2.3x
Sun, 02 Mar 2025DKK 5.4tDKK 1.9tDKK 264.5b13.7x20.5x2.9x
Tue, 28 Jan 2025DKK 5.2tDKK 1.8tDKK 237.8b14.1x21.9x2.9x
Thu, 26 Dec 2024DKK 5.2tDKK 1.8tDKK 238.3b13.9x22x2.9x
Sat, 23 Nov 2024DKK 5.9tDKK 1.8tDKK 237.8b14.2x24.7x3.2x
Mon, 21 Oct 2024DKK 6.2tDKK 1.7tDKK 181.1b15.7x34.2x3.5x
Wed, 18 Sep 2024DKK 6.7tDKK 1.7tDKK 180.1b15.9x36.9x3.8x
Fri, 16 Aug 2024DKK 6.7tDKK 1.7tDKK 181.1b16.5x36.9x3.9x
Sun, 14 Jul 2024DKK 6.9tDKK 1.7tDKK 185.3b14.8x37.4x4x
Tue, 11 Jun 2024DKK 7.0tDKK 1.7tDKK 184.7b14.9x37.6x4.1x
Thu, 09 May 2024DKK 6.5tDKK 1.7tDKK 183.7b14.8x35.2x3.8x
Sat, 06 Apr 2024DKK 6.4tDKK 1.7tDKK 192.4b14.7x33.1x3.7x
Mon, 04 Mar 2024DKK 6.3tDKK 1.7tDKK 192.2b13.7x32.8x3.7x
Wed, 31 Jan 2024DKK 5.8tDKK 1.8tDKK 217.0b14x26.8x3.3x
Fri, 29 Dec 2023DKK 5.5tDKK 1.8tDKK 215.8b13.6x25.7x3.1x
Sun, 26 Nov 2023DKK 5.5tDKK 1.8tDKK 216.5b13.2x25.3x3.1x
Tue, 24 Oct 2023DKK 5.2tDKK 1.9tDKK 284.0b12.5x18.5x2.8x
Thu, 21 Sep 2023DKK 5.4tDKK 1.9tDKK 282.8b13x19.1x2.9x
Sat, 19 Aug 2023DKK 5.3tDKK 1.9tDKK 280.2b13.1x18.8x2.8x
Mon, 17 Jul 2023DKK 5.0tDKK 1.9tDKK 318.0b13.4x15.8x2.6x
Wed, 14 Jun 2023DKK 5.1tDKK 1.9tDKK 324.4b14.1x15.8x2.6x
Fri, 12 May 2023DKK 5.3tDKK 1.9tDKK 320.9b14.2x16.4x2.7x
Sun, 09 Apr 2023DKK 4.9tDKK 1.9tDKK 343.9b14.9x14.2x2.5x
Tue, 07 Mar 2023DKK 4.8tDKK 1.9tDKK 346.5b14.4x13.9x2.5x
Thu, 02 Feb 2023DKK 4.6tDKK 1.9tDKK 353.7b13.8x13x2.4x
Price to Earnings Ratio

13x


Total Market Cap: DKK 4.6tTotal Earnings: DKK 353.7bTotal Revenue: DKK 1.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Market Price to Earnings3Y Average 22.2x202420252026
Current Market PE
  • Investors are pessimistic on the Danish market, indicating that they anticipate earnings will not grow as fast as they have historically.
  • The market is trading at a PE ratio of 17.4x which is lower than its 3-year average PE of 22.2x.
Past Earnings Growth
  • The earnings for Danish listed companies have declined 9.7% per year over the last three years.
  • Meanwhile revenues have been flat.
  • This means that either the cost of doing business or the level of investment back into businesses is increasing since sales have remained steady while profits have fallen.

Sector Trends

Which sectors have driven the changes within the Danish Market?

DK Market2.52%
Healthcare5.35%
Telecom2.49%
Utilities1.66%
Tech0.44%
Consumer Staples-0.11%
Industrials-0.25%
Materials-0.38%
Financials-0.40%
Consumer Discretionary-1.32%
Energy-1.36%
Real Estate-1.60%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading close to its 3-year average PE ratio of 52.4x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 56.0% which is higher than its past year's earnings decline of 17.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 56% over the next 5 years.
  • This is better than its past earnings decline of 17% per year.
  • In contrast, the Energy sector is expected to see its earnings decline by 35% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NOVO B Novo NordiskDKK 401.356.3%
+DKK 105.8b		-35.5%PE17.2xHealthcare
GMAB GenmabDKK 2.13k4.3%
+DKK 5.4b		41.4%PE13.1xHealthcare
ORSTED ØrstedDKK 137.751.7%
+DKK 3.0b		-48.2%PS2.6xUtilities
ROCK B RockwoolDKK 211.855.0%
+DKK 2.1b		-17.7%PE11.8xIndustrials
ZEAL Zealand PharmaDKK 426.006.4%
+DKK 1.8b		-44.7%PE4.6xHealthcare
See more

Market Insights

Header cover image
How to invest when commodity prices get messy ⚖️
Richard Bowman avatar
Richard Bowman
|
|
From miners to energy, 2026 may reward structure and margins over spot price bets.
Continue reading
Why Didn’t Oil React to Venezuela? 🇻🇪
Last Week

Why Didn’t Oil React to Venezuela? 🇻🇪

Latest News

MAERSK B
DKK 14,410.00
A.P. Møller - Mærsk
7D
-1.9%
1Y
37.2%

MAERSK B: Prolonged Transport Weakness Will Outweigh Profit Margins Going Forward

Analysts have trimmed their fair value estimate for A.P. Møller - Mærsk from DKK 11,991.74 to DKK 11,589.21, reflecting more cautious price targets after several recent downgrades and mixed target revisions across major banks. Analyst Commentary Recent research on A.P. Møller - Mærsk points to a split view, with some analysts trimming targets and ratings while others still see room for value at different price levels.
DEMANT
DKK 230.00
Demant
7D
3.1%
1Y
-20.1%

DEMANT: Stable Guidance And Sector Perform Rating Will Support Future Earnings Resilience

Analysts have reduced their price target on Demant by roughly DKK 2 to about DKK 266, reflecting only modest adjustments to growth, margin and P/E assumptions and citing limited scope for the company to increase its organic revenue share over the medium term. Analyst Commentary Recent research paints a fairly balanced picture for Demant, with the current DKK 250 price target and Sector Perform rating pointing to a view that the shares are reasonably valued on existing growth and margin assumptions.
ALMB
DKK 18.16
Alm. Brand
7D
-1.4%
1Y
21.1%

Alm. Brand (CPH:ALMB) Has Announced That It Will Be Increasing Its Dividend To DKK0.66

Jan 24
Alm. Brand (CPH:ALMB) Has Announced That It Will Be Increasing Its Dividend To DKK0.66
TRYG
DKK 152.90
Tryg
7D
-5.4%
1Y
4.5%
ALK B
DKK 219.40
ALK-Abelló
7D
-0.6%
1Y
41.4%

Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity

Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?
NOVO B
DKK 401.35
Novo Nordisk
7D
6.3%
1Y
-35.5%

NOVO B: Wegovy Pill Launch And Execution Discipline Will Support Future Upside

Analysts have reduced their fair value estimate for Novo Nordisk to €540 from €612. They cite more moderate assumptions for revenue growth and profit margins, along with a higher discount rate and a slightly higher expected future P/E multiple.
RILBA
DKK 1,619.00
Ringkjøbing Landbobank
7D
4.6%
1Y
38.6%
VWS
DKK 179.35
Vestas Wind Systems
7D
-1.2%
1Y
88.9%

VWS: Higher Price View Will Face Pressure From Execution And Margin Risks

Analysts have lifted their price target on Vestas Wind Systems, with one recent move taking it to DKK 173 from DKK 164. The change reflects updates to fair value assumptions, discount rate, revenue growth expectations, profit margin outlook and future P/E inputs.
ROCK B
DKK 211.85
Rockwool
7D
5.0%
1Y
-17.7%

ROCK B: Bullish Coverage And Buybacks Are Expected To Support Rebound

Analysts have trimmed their fair value estimate for Rockwool from DKK 359.88 to DKK 280.16, reflecting updated assumptions for slower revenue growth, slightly lower margins and a more cautious future P/E, even as recent research includes both new bullish coverage and moderated price targets. Analyst Commentary Recent research on Rockwool shows a mix of caution and optimism, with several bullish analysts focusing on valuation support, an improving earnings backdrop and potential for more balanced execution after previous downgrades.
PNDORA
DKK 505.00
Pandora
7D
-2.8%
1Y
-62.9%

PNDORA: Lower Margin Outlook Will Shape Measured Expectations For Future Earnings Multiple

Analysts now see Pandora's fair value at €510, down from €630. They cite modestly lower revenue growth and profit margin assumptions, along with a slightly higher discount rate and a trimmed future P/E estimate.
GMAB
DKK 2,130.00
Genmab
7D
4.3%
1Y
41.4%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
HLUN B
DKK 45.56
H. Lundbeck
7D
3.4%
1Y
9.8%

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
ZEAL
DKK 426.00
Zealand Pharma
7D
6.4%
1Y
-44.7%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
KBHL
DKK 6,460.00
Københavns Lufthavne
7D
-2.1%
1Y
2.5%
ORSTED
DKK 137.75
Ørsted
7D
1.7%
1Y
-48.2%
NSIS B
DKK 404.10
Novozymes
7D
-0.4%
1Y
-1.2%